Bevacizumab and non-small-cell lung cancer: Starving the enemy to survive

Francesco Grossi, Marianna Aita

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Although platinum-based chemotherapy remains a mainstay of non-small-cell lung cancer treatment, its efficacy has probably reached a plateau. Increased understanding of cancer biology has allowed the identification of a number of possible molecular targets, including the EGF receptor and the angiogenesis pathway. ECOG-E4599 has randomised chemonaive patients to receive paclitaxel - carboplatin with and without bevacizumab, a humanised monoclonal antibody targeting the VEGF. The study is the first to show a survival advantage of adding a biological agent to chemotherapy in this setting: in particular, for the first time the survival of lung cancer patients has been extended beyond 1 year. The aim of this review is to describe the biological and clinical properties of bevacizumab and to discuss the evidence that has supported its approval for the first-line treatment of advanced non-squamous non-small-cell lung cancer.

Original languageEnglish
Pages (from-to)1107-1119
Number of pages13
JournalExpert Opinion on Biological Therapy
Volume7
Issue number7
DOIs
Publication statusPublished - Jul 2007

Fingerprint

Chemotherapy
Non-Small Cell Lung Carcinoma
Cells
Antibodies, Monoclonal, Humanized
Drug Therapy
Oncology
Survival
Carboplatin
Biological Factors
Paclitaxel
Platinum
Epidermal Growth Factor Receptor
Vascular Endothelial Growth Factor A
Lung Neoplasms
Neoplasms
Bevacizumab
Therapeutics

Keywords

  • Angiogenesis
  • Bevacizumab
  • Non-small-cell lung cancer
  • Targeted therapies

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology
  • Pharmacology

Cite this

Bevacizumab and non-small-cell lung cancer : Starving the enemy to survive. / Grossi, Francesco; Aita, Marianna.

In: Expert Opinion on Biological Therapy, Vol. 7, No. 7, 07.2007, p. 1107-1119.

Research output: Contribution to journalArticle

@article{62abdce4de70461b884cbcff57169dfd,
title = "Bevacizumab and non-small-cell lung cancer: Starving the enemy to survive",
abstract = "Although platinum-based chemotherapy remains a mainstay of non-small-cell lung cancer treatment, its efficacy has probably reached a plateau. Increased understanding of cancer biology has allowed the identification of a number of possible molecular targets, including the EGF receptor and the angiogenesis pathway. ECOG-E4599 has randomised chemonaive patients to receive paclitaxel - carboplatin with and without bevacizumab, a humanised monoclonal antibody targeting the VEGF. The study is the first to show a survival advantage of adding a biological agent to chemotherapy in this setting: in particular, for the first time the survival of lung cancer patients has been extended beyond 1 year. The aim of this review is to describe the biological and clinical properties of bevacizumab and to discuss the evidence that has supported its approval for the first-line treatment of advanced non-squamous non-small-cell lung cancer.",
keywords = "Angiogenesis, Bevacizumab, Non-small-cell lung cancer, Targeted therapies",
author = "Francesco Grossi and Marianna Aita",
year = "2007",
month = "7",
doi = "10.1517/14712598.7.7.1107",
language = "English",
volume = "7",
pages = "1107--1119",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "7",

}

TY - JOUR

T1 - Bevacizumab and non-small-cell lung cancer

T2 - Starving the enemy to survive

AU - Grossi, Francesco

AU - Aita, Marianna

PY - 2007/7

Y1 - 2007/7

N2 - Although platinum-based chemotherapy remains a mainstay of non-small-cell lung cancer treatment, its efficacy has probably reached a plateau. Increased understanding of cancer biology has allowed the identification of a number of possible molecular targets, including the EGF receptor and the angiogenesis pathway. ECOG-E4599 has randomised chemonaive patients to receive paclitaxel - carboplatin with and without bevacizumab, a humanised monoclonal antibody targeting the VEGF. The study is the first to show a survival advantage of adding a biological agent to chemotherapy in this setting: in particular, for the first time the survival of lung cancer patients has been extended beyond 1 year. The aim of this review is to describe the biological and clinical properties of bevacizumab and to discuss the evidence that has supported its approval for the first-line treatment of advanced non-squamous non-small-cell lung cancer.

AB - Although platinum-based chemotherapy remains a mainstay of non-small-cell lung cancer treatment, its efficacy has probably reached a plateau. Increased understanding of cancer biology has allowed the identification of a number of possible molecular targets, including the EGF receptor and the angiogenesis pathway. ECOG-E4599 has randomised chemonaive patients to receive paclitaxel - carboplatin with and without bevacizumab, a humanised monoclonal antibody targeting the VEGF. The study is the first to show a survival advantage of adding a biological agent to chemotherapy in this setting: in particular, for the first time the survival of lung cancer patients has been extended beyond 1 year. The aim of this review is to describe the biological and clinical properties of bevacizumab and to discuss the evidence that has supported its approval for the first-line treatment of advanced non-squamous non-small-cell lung cancer.

KW - Angiogenesis

KW - Bevacizumab

KW - Non-small-cell lung cancer

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=34547614650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547614650&partnerID=8YFLogxK

U2 - 10.1517/14712598.7.7.1107

DO - 10.1517/14712598.7.7.1107

M3 - Article

C2 - 17665997

AN - SCOPUS:34547614650

VL - 7

SP - 1107

EP - 1119

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 7

ER -